Ixekizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and NICE (England), among others, recommended or restricted ixekizumab, while AWMSG (Wales) did not recommend it.
CONITEC (Brazil) has been harder on ixekizumab than on its own caseload: it refused 5 of 6 decisive submissions here (83%), against a base rate of 44% across everything it has assessed.
Assessment has run over 9.8 years, from 14 Jun 2016 at AWMSG (Wales) to 19 Mar 2026 at G-BA (Germany).
HAS (France) changed its position: not recommended on 5 Oct 2016, recommended by 11 Jul 2022, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for ixekizumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 10 of 41 records date from 2023 or later.
The programme is broad: 14 distinct indication wordings are recorded for ixekizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 41 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ixekizumab, on 14 Jun 2016; PHARMAC (New Zealand) did not open a file until 17 Jun 2025 — an unusually long tail of 9 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 11 years in total.
Restriction is doing real work here: 8 of 31 decisive outcomes narrowed ixekizumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and SMC (Scotland) among others.
10 of the 11 agencies here assessed ixekizumab more than once, PBAC (Australia) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for ixekizumab.
The full ledger for ixekizumab reads 13 recommended, 10 not recommended, 8 restricted and 4 no benefit, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 19 Mar 2026 | Taltz — benefit assessment §35a | added benefit: not proven | source |
| PBAC (Australia) | 2025 | Non-radiographic axial spondyloarthritis | The PBAC rescinded the November 2021 recommendation for this drug. | source |
| PHARMAC (New Zealand) | 17 Jun 2025 | Inflammatory conditions | funding application decided · decision reached | source |
| CONITEC (Brazil) | 15 Jan 2025 | Tratamento de pacientes adultos com artrite psoriásica que falharam ou mostraramse intolerantes ao biológico de primiera… | incorporated into SUS | source |
| HAS (France) | 5 Oct 2016 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
36 further decisions for ixekizumab, across 10 agencies, are not shown here. They include the most recent record on file, 19 Mar 2026 from G-BA (Germany); its outcome is in the subscriber dataset. They link to 22 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 41 decisions for ixekizumab from 11 agencies, 2016 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.